Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment.

Tumor penetrating peptides for improved drug delivery. Adv Drug Deliv Rev (2016) 0.79

Core-shell nanoparticle-based peptide therapeutics and combined hyperthermia for enhanced cancer cell apoptosis. ACS Nano (2014) 0.78

How to unleash mitochondrial apoptotic blockades to kill cancers? Acta Pharm Sin B (2016) 0.75

An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell (2002) 11.09

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science (2007) 10.60

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell (2006) 10.19

RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol (1996) 9.77

Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell (1985) 8.55

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 8.11

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 7.63

Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science (2010) 6.01

Organ targeting in vivo using phage display peptide libraries. Nature (1996) 5.20

Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07

Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell (2009) 4.02

A stapled BID BH3 helix directly binds and activates BAX. Mol Cell (2006) 3.86

Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med (1999) 3.72

Synthetic therapeutic peptides: science and market. Drug Discov Today (2009) 2.95

De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem (1996) 2.55

C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A (2009) 2.41

Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem (1993) 2.37

Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol (1999) 2.34

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol (2000) 2.18

RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm (2012) 1.84

Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res (2005) 1.60

Integrin alpha(v)beta(3) mediates rotavirus cell entry. Proc Natl Acad Sci U S A (2000) 1.56

Role of the alpha-amino group of protein in ubiquitin-mediated protein breakdown. Proc Natl Acad Sci U S A (1984) 1.49

Cancer treatment using peptides: current therapies and future prospects. J Amino Acids (2012) 1.23

Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. Biochemistry (1995) 1.20

ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem (2008) 1.19

Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol (2009) 1.11

Therapeutic peptides. Trends Biotechnol (2003) 1.08

Targeting mitochondria for cancer therapy. Environ Mol Mutagen (2010) 1.03

Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans (2007) 1.01

Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides. Front Microbiol (2013) 0.98

NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res (2013) 0.96

Elevated Orai1 expression mediates tumor-promoting intracellular Ca2+ oscillations in human esophageal squamous cell carcinoma. Oncotarget (2014) 0.95

Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model. Acta Biochim Pol (2006) 0.94

The tail-anchoring domain of Bfl1 and HCCS1 targets mitochondrial membrane permeability to induce apoptosis. J Cell Sci (2007) 0.93

Conversion of Bfl-1, an anti-apoptotic Bcl-2 family protein, to a potent pro-apoptotic protein by fusion with green fluorescent protein (GFP). FEBS Lett (2003) 0.90

Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging. Bioorg Med Chem Lett (2010) 0.87

Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 (BH3) peptides from Bcl-2 family proteins induce apoptosis through different mechanisms. J Biol Chem (2010) 0.86

Therapeutic peptides: Targeting the mitochondrion to modulate apoptosis. Biochim Biophys Acta (2006) 0.85

Targeting malignant mitochondria with therapeutic peptides. Ther Deliv (2012) 0.84

In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs. J Pharmacol Exp Ther (2002) 0.79

Unreliability of the cytochrome c-enhanced green fluorescent fusion protein as a marker of cytochrome c release in cells that overexpress Bcl-2. J Biol Chem (2001) 0.78

The tumor suppressive role of NUMB isoform 1 in esophageal squamous cell carcinoma. Oncotarget (2014) 0.82

Transplantation of placenta-derived mesenchymal stem cells enhances angiogenesis after ischemic limb injury in mice. J Cell Mol Med (2015) 0.78

PTRF suppresses the progression of colorectal cancers. Oncotarget (2017) 0.76